Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

7.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.1K
3.1K
Cancer Prevention02:59

Cancer Prevention

8.7K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor regression pattern and distribution of residual tumor cells in potential candidates for local excision of rectal cancer: a prospective cohort study.

Techniques in coloproctology·2026
Same author

AAV-Driven miR-146a Promotes Neurite Outgrowth and Axonal Regeneration in Cortical Neurons.

Journal of neurochemistry·2026
Same author

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

ESMO open·2025
Same author

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).

Breast cancer research : BCR·2025
Same author

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024
Same author

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Related Experiment Video

Updated: Mar 30, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.5K

Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer.

A Nogueira-Rodrigues1, A C Melo, G Werutsky

  • 1UFMG, Federal University, Minas Gerais, Brazil, Clinical Research Department, Rua Alfredo Balena, 110. 2o andar. Belo Horizonte, Minas Gerais, Brazil. angelica.onco@uol.com.br.

Current Cancer Drug Targets
|November 19, 2015
PubMed
Summary

High-risk human papillomavirus (HPV) drives cervical cancer (CC). New targeted therapies, like bevacizumab and adoptive T cell therapy, show promise for advanced CC, addressing an urgent need for effective treatments.

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.4K
Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
07:43

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

10.4K

Related Experiment Videos

Last Updated: Mar 30, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.5K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.4K
Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
07:43

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

10.4K

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Cervical cancer (CC) is a leading cause of cancer death in women, strongly linked to high-risk human papillomavirus (HPV) infections.
  • Despite early successes with cisplatin chemotherapy, clinical trials for CC have been limited, creating an urgent need for more effective therapies, especially for advanced, recurrent, or metastatic disease.

Purpose of the Study:

  • To review molecular aspects of HPV infection in cervical cancer.
  • To summarize updated drug development data for advanced CC.
  • To discuss future challenges and prospects for cervical cancer treatment.

Main Methods:

  • Literature review focusing on molecular mechanisms of HPV-driven cervical carcinogenesis.
  • Analysis of recent clinical trial data for novel therapeutic agents in advanced CC.
  • Exploration of diverse biologic pathways implicated in CC development and progression.

Main Results:

  • The commonality of high-risk HPV infection and viral oncoprotein expression in CC presents unique opportunities for disease control.
  • Bevacizumab, an antiangiogenic agent, has demonstrated increased overall survival in advanced CC patients.
  • HPV-targeted adoptive T cell therapy has achieved durable complete responses in metastatic CC patients.

Conclusions:

  • Novel therapeutic strategies beyond conventional chemoradiation and chemotherapy are crucial for managing advanced cervical cancer.
  • Targeting molecular pathways, including those related to HPV, offers promising avenues for improved patient outcomes.
  • Continued research and drug development are essential to overcome challenges and advance the treatment landscape for cervical cancer.